The Role of Cholesterol Metabolism in Alzheimer’s Disease

Molecular Neurobiology

Volumn 51, Issue 3, 2015, Pages 947-965

  Sun, Jia Hao ^a   Yu, Jin Tai ^a   Tan, Lan ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Beta amyloid; Cholesterol; Pathogenesis; Phosphorylated tau; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL;

ALZHEIMER DISEASE; ANIMAL; BRAIN; HUMAN; LIPID METABOLISM; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CHOLESTEROL; HUMANS; LIPID METABOLISM;

EID: 84939885240     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8749-y     Document Type: Review

References (222)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheim Dement: JAlzheim Assoc 3(3):186–191. doi:10.1016/j.jalz.2007.04.381
2. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126(1):88–94. doi:10.1006/exnr.1994.1044
3. Adlard PA, Cummings BJ (2004) Alzheimer’s disease—a sum greater than its parts? Neurobiol Aging 25(6):725–733. doi:10.1016/j.neurobiolaging.2003.12.016, discussion 743-726
4. Tharp WG, Sarkar IN (2013) Origins of amyloid-beta. BMC Genomics 14:290. doi:10.1186/1471-2164-14-290
5. Coughlan CM, Breen KC (2000) Factors influencing the processing and function of the amyloid beta precursor protein—a potential therapeutic target in Alzheimer's disease? Pharmacol Ther 86(2):111–145
6. Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56(4):321–339
7. Maulik M, Westaway D, Jhamandas JH, Kar S (2013) Role of cholesterol in APP metabolism and its significance in Alzheimer’s disease pathogenesis. Mol Neurobiol 47(1):37–63. doi:10.1007/s12035-012-8337-y
8. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, Octave JN, Pradier L, Touchet N, Tremp G (2001) Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 67:81–88
9. Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, Graff-Radford NR, Dickson DW, Murray ME (2012) Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 124(5):681–692. doi:10.1007/s00401-012-1044-y
10. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330(6012):1774. doi:10.1126/science.1197623
11. Jiang T, Yu JT, Tian Y, Tan L (2013) Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr Alzheimer Res 10(8):852–867
12. Dietschy JM, Turley SD (2004) Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45(8):1375–1397
13. Bjorkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler, Thromb, Vasc Biol 24(5):806–815. doi:10.1161/01.ATV.0000120374.59826.1b
14. Funfschilling U, Saher G, Xiao L, Mobius W, Nave KA (2007) Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci 8:1. doi:10.1186/1471-2202-8-1
15. Mazein A, Watterson S, Hsieh WY, Griffiths WJ, Ghazal P (2013) A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway. Biochem Pharmacol 86(1):56–66. doi:10.1016/j.bcp.2013.03.021
16. Bengoechea-Alonso MT, Ericsson J (2007) SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol 19(2):215–222. doi:10.1016/j.ceb.2007.02.004
17. Ye J, DeBose-Boyd RA (2011) Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol 3(7):a004754. doi:10.1101/cshperspect.a004754
18. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J (1998) Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39(8):1594–1600
19. Jurevics H, Morell P (1995) Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64(2):895–901
20. Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer’s disease: an update. Annu Rev Neurosci 37:79–100
21. Vance JE, Hayashi H, Karten B (2005) Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 16(2):193–212. doi:10.1016/j.semcdb.2005.01.005
22. Brown AJ, Jessup W (2009) Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 30(3):111–122. doi:10.1016/j.mam.2009.02.005
23. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917(1):148–161
24. Bjorkhem I (2007) Rediscovery of cerebrosterol. Lipids 42(1):5–14. doi:10.1007/s11745-006-1003-2
25. Lund EG, Guileyardo JM, Russell DW (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A 96(13):7238–7243
26. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Bjorkhem I (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J Lipid Res 45(1):186–193. doi:10.1194/jlr.M300320-JLR200
27. Saucier SE, Kandutsch AA, Clark DS, Spencer TA (1993) Hepatic uptake and metabolism of ingested 24-hydroxycholesterol and 24 (S),25-epoxycholesterol. Biochim Biophys Acta 1166(1):115–123
28. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278(25):22980–22988. doi:10.1074/jbc.M303415200
29. Martin M, Dotti CG, Ledesma MD (2010) Brain cholesterol in normal and pathological aging. Biochim Biophys Acta 1801(8):934–944. doi:10.1016/j.bbalip.2010.03.011
30. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS (2003) 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem 278(15):13244–13256. doi:10.1074/jbc.M300044200
31. Panzenboeck U, Balazs Z, Sovic A, Hrzenjak A, Levak-Frank S, Wintersperger A, Malle E, Sattler W (2002) ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem 277(45):42781–42789. doi:10.1074/jbc.M207601200
32. Koldamova R, Fitz NF, Lefterov I (2010) The role of ATP-binding cassette transporter A1 in Alzheimer’s disease and neurodegeneration. Biochim Biophys Acta 1801(8):824–830. doi:10.1016/j.bbalip.2010.02.010
33. Dietschy JM (2009) Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 390(4):287–293. doi:10.1515/BC.2009.035
34. Wang H, Eckel RH (2014) What are lipoproteins doing in the brain? Trends Endocrinol Metabol 25(1):8–14. doi:10.1016/j.tem.2013.10.003
35. Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46(5):1047–1052. doi:10.1194/jlr.M500024-JLR200
36. Martin KO, Reiss AB, Lathe R, Javitt NB (1997) 7 Alpha-hydroxylation of 27-hydroxycholesterol: biologic role in the regulation of cholesterol synthesis. J Lipid Res 38(5):1053–1058
37. Meaney S, Heverin M, Panzenboeck U, Ekstrom L, Axelsson M, Andersson U, Diczfalusy U, Pikuleva I, Wahren J, Sattler W, Bjorkhem I (2007) Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res 48(4):944–951. doi:10.1194/jlr.M600529-JLR200
38. Sodhi RK, Singh N (2013) Liver X receptors: emerging therapeutic targets for Alzheimer’s disease. Pharmacol Res: Off J Ital Pharmacol Soc 72:45–51. doi:10.1016/j.phrs.2013.03.008
39. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P (2001) LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 98(2):507–512. doi:10.1073/pnas.021488798
40. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368(9533):387–403. doi:10.1016/S0140-6736(06)69113-7
41. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discovery 10(9):698–712. doi:10.1038/nrd3505
42. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112. doi:10.1038/nrm2101
43. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108(14):5819–5824. doi:10.1073/pnas.1017033108
44. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. doi:10.1126/science.1072994
45. Vassar R (2004) BACE1—the beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 23(1–2):105–113. doi:10.1385/jmn:23:1-2:105
46. Vassar R (2013) ADAM10 prodomain mutations cause late-onset Alzheimer’s disease: not just the latest FAD. Neuron 80(2):250–253. doi:10.1016/j.neuron.2013.09.031
47. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29(17):3020–3032. doi:10.1038/emboj.2010.167
48. Mayeux R, St George-Hyslop P (2009) Brain traffic: subcellular transport of the amyloid precursor protein. Arch Neurol 66(4):433–434. doi:10.1001/archneurol.2009.29
49. Small SA, Gandy S (2006) Sorting through the cell biology of Alzheimer’s disease: intracellular pathways to pathogenesis. Neuron 52(1):15–31. doi:10.1016/j.neuron.2006.09.001
50. Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, Ren Z, Jansen-West K, Malphrus K, Eggert S, Maruyama H, Cottrell BA, Das P, Basi GS, Koo EH, Golde TE (2011) Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid beta peptide length: support for a sequential model of gamma-secretase intramembrane proteolysis and regulation by the amyloid beta precursor protein (APP) juxtamembrane region. J Biol Chem 286(46):39804–39812. doi:10.1074/jbc.M111.274696
51. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci: Off J Soc Neurosci 29(41):13042–13052. doi:10.1523/JNEUROSCI.2362-09.2009
52. Hamley IW (2012) The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization. Chem Rev 112(10):5147–5192. doi:10.1021/cr3000994
53. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE (2002) Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 9(1):11–23. doi:10.1006/nbdi.2001.0470
54. Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita T, Iwatsubo T, Hamakubo T, Kodama T (2005) Association of active gamma-secretase complex with lipid rafts. J Lipid Res 46(5):904–912. doi:10.1194/jlr.M400333-JLR200
55. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G (2005) Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 280(27):25892–25900. doi:10.1074/jbc.M503570200
56. Fonseca AC, Resende R, Oliveira CR, Pereira CM (2010) Cholesterol and statins in Alzheimer’s disease: current controversies. Exp Neurol 223(2):282–293. doi:10.1016/j.expneurol.2009.09.013
57. Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271(8):4436–4440
58. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 98(10):5815–5820. doi:10.1073/pnas.081612998
59. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, Sue LI, Woulfe J, Xu H, Stanimirovic DB, Zhang W (2008) Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 29(3):422–437. doi:10.1016/j.nbd.2007.10.005
60. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160(1):113–123. doi:10.1083/jcb.200207113
61. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K (2005) Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280(44):36815–36823. doi:10.1074/jbc.M504484200
62. Sharman MJ, Moussavi Nik SH, Chen MM, Ong D, Wijaya L, Laws SM, Taddei K, Newman M, Lardelli M, Martins RN, Verdile G (2013) The guinea pig as a model for sporadic Alzheimer’s disease (AD): the impact of cholesterol intake on expression of AD-related genes. PLoS One 8(6):e66235. doi:10.1371/journal.pone.0066235
63. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336(6085):1168–1171. doi:10.1126/science.1219988
64. Vanier MT, Millat G (2003) Niemann-Pick disease type C. Clin Genet 64(4):269–281
65. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164(3):975–985
66. Kodam A, Maulik M, Peake K, Amritraj A, Vetrivel KS, Thinakaran G, Vance JE, Kar S (2010) Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. Glia 58(11):1267–1281. doi:10.1002/glia.21001
67. Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K (2003) Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci: Off J Soc Neurosci 23(13):5645–5649
68. Malnar M, Kosicek M, Lisica A, Posavec M, Krolo A, Njavro J, Omerbasic D, Tahirovic S, Hecimovic S (2012) Cholesterol-depletion corrects APP and BACE1 misstrafficking in NPC1-deficient cells. Biochim Biophys Acta 1822(8):1270–1283. doi:10.1016/j.bbadis.2012.04.002
69. Cibickova L, Hyspler R, Micuda S, Cibicek N, Zivna H, Jun D, Ticha A, Brcakova E, Palicka V (2009) The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain. Steroids 74(1):13–19. doi:10.1016/j.steroids.2008.08.007
70. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters CL, Li QX (2004) APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis 16(1):124–132. doi:10.1016/j.nbd.2004.01.009
71. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167(5):953–960. doi:10.1083/jcb.200404149
72. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A (2009) Beta-amyloid monomers are neuroprotective. J Neurosci: Off J Soc Neurosci 29(34):10582–10587. doi:10.1523/JNEUROSCI.1736-09.2009
73. Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15(3):349–357. doi:10.1038/nn.3028
74. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35(3):352–358. doi:10.1016/j.nbd.2009.05.024
75. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284(8):4749–4753. doi:10.1074/jbc.R800036200
76. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14(8):837–842. doi:10.1038/nm1782
77. Schneider A, Schulz-Schaeffer W, Hartmann T, Schulz JB, Simons M (2006) Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis 23(3):573–577. doi:10.1016/j.nbd.2006.04.015
78. Qiu L, Lewis A, Como J, Vaughn MW, Huang J, Somerharju P, Virtanen J, Cheng KH (2009) Cholesterol modulates the interaction of beta-amyloid peptide with lipid bilayers. Biophys J 96(10):4299–4307. doi:10.1016/j.bpj.2009.02.036
79. Manna M, Mukhopadhyay C (2013) Binding, conformational transition and dimerization of amyloid-beta peptide on GM1-containing ternary membrane: insights from molecular dynamics simulation. PLoS One 8(8):e71308. doi:10.1371/journal.pone.0071308
80. Matsuzaki K (2007) Physicochemical interactions of amyloid beta-peptide with lipid bilayers. Biochim Biophys Acta 1768(8):1935–1942. doi:10.1016/j.bbamem.2007.02.009
81. Ogawa M, Tsukuda M, Yamaguchi T, Ikeda K, Okada T, Yano Y, Hoshino M, Matsuzaki K (2011) Ganglioside-mediated aggregation of amyloid beta-proteins (Abeta): comparison between Abeta-(1-42) and Abeta-(1-40). J Neurochem 116(5):851–857. doi:10.1111/j.1471-4159.2010.06997.x
82. Ariga T, McDonald MP, Yu RK (2008) Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease—a review. J Lipid Res 49(6):1157–1175. doi:10.1194/jlr.R800007-JLR200
83. Mori K, Mahmood MI, Neya S, Matsuzaki K, Hoshino T (2012) Formation of GM1 ganglioside clusters on the lipid membrane containing sphingomyeline and cholesterol. J Phys Chem B 116(17):5111–5121. doi:10.1021/jp207881k
84. Abramov AY, Ionov M, Pavlov E, Duchen MR (2011) Membrane cholesterol content plays a key role in the neurotoxicity of beta-amyloid: implications for Alzheimer’s disease. Aging Cell 10(4):595–603. doi:10.1111/j.1474-9726.2011.00685.x
85. Arispe N, Doh M (2002) Plasma membrane cholesterol controls the cytotoxicity of Alzheimer’s disease AbetaP (1-40) and (1-42) peptides. FASEB J: Off Publ Fed Am Soc Exp Biol 16(12):1526–1536. doi:10.1096/fj.02-0829com
86. Lin MS, Chen LY, Wang SS, Chang Y, Chen WY (2008) Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide. Colloids Surf, B 65(2):172–177. doi:10.1016/j.colsurfb.2008.03.012
87. Mendoza-Oliva A, Ferrera P, Arias C (2013) Interplay between cholesterol and homocysteine in the exacerbation of amyloid-beta toxicity in human neuroblastoma cells. CNS Neurol Disord: Drug Targets 12(6):842–848
88. Phan HT, Hata T, Morita M, Yoda T, Hamada T, Vestergaard MC, Takagi M (2013) The effect of oxysterols on the interaction of Alzheimer’s amyloid beta with model membranes. Biochim Biophys Acta 1828(11):2487–2495. doi:10.1016/j.bbamem.2013.06.021
89. Yao ZX, Brown RC, Teper G, Greeson J, Papadopoulos V (2002) 22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytotoxicity by binding to beta-amyloid peptide. J Neurochem 83(5):1110–1119
90. Lecanu L, Rammouz G, McCourty A, Sidahmed EK, Greeson J, Papadopoulos V (2010) Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer’s disease. Neuroscience 165(2):427–435. doi:10.1016/j.neuroscience.2009.10.033
91. Papadopoulos V, Lecanu L (2012) Caprospinol: discovery of a steroid drug candidate to treat Alzheimer’s disease based on 22R-hydroxycholesterol structure and properties. J Neuroendocrinol 24(1):93–101. doi:10.1111/j.1365-2826.2011.02167.x
92. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer’s disease. Brain Pathol 18(2):240–252. doi:10.1111/j.1750-3639.2008.00132.x
93. Bulloj A, Leal MC, Surace EI, Zhang X, Xu H, Ledesma MD, Castano EM, Morelli L (2008) Detergent resistant membrane-associated IDE in brain tissue and cultured cells: relevance to Abeta and insulin degradation. Mol Neurodegener 3:22. doi:10.1186/1750-1326-3-22
94. Glebov K, Walter J (2012) Statins in unconventional secretion of insulin-degrading enzyme and degradation of the amyloid-beta peptide. Neuro-degenerative Dis 10(1–4):309–312. doi:10.1159/000332595
95. Kanemitsu H, Tomiyama T, Mori H (2003) Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350(2):113–116
96. Sato K, Tanabe C, Yonemura Y, Watahiki H, Zhao Y, Yagishita S, Ebina M, Suo S, Futai E, Murata M, Ishiura S (2012) Localization of mature neprilysin in lipid rafts. J Neurosci Res 90(4):870–877. doi:10.1002/jnr.22796
97. Hicks DA, Nalivaeva NN, Turner AJ (2012) Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signaling. Front Physiol 3:189. doi:10.3389/fphys.2012.00189
98. Wang J, Ohno-Matsui K, Morita I (2012) Cholesterol enhances amyloid beta deposition in mouse retina by modulating the activities of Abeta-regulating enzymes in retinal pigment epithelial cells. Biochem Biophys Res Commun 424(4):704–709. doi:10.1016/j.bbrc.2012.07.014
99. Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD, Mohajeri MH (2006) The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 25(2):432–443. doi:10.1038/sj.emboj.7600938
100. Stefani M, Liguri G (2009) Cholesterol in Alzheimer’s disease: unresolved questions. Curr Alzheimer Res 6(1):15–29
101. Lee CY, Tse W, Smith JD, Landreth GE (2012) Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 287(3):2032–2044. doi:10.1074/jbc.M111.295451
102. Hermann DM, ElAli A (2012) The abluminal endothelial membrane in neurovascular remodeling in health and disease. Science Signaling 5 (236):re4. doi:10.1126/scisignal.2002886
103. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides—implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17(4):347–353. doi:10.1111/j.1750-3639.2007.00075.x
104. Hartz AM, Miller DS, Bauer B (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol Pharmacol 77(5):715–723. doi:10.1124/mol.109.061754
105. Qosa H, Abuznait AH, Hill RA, Kaddoumi A (2012) Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer’s disease. J Alzheim Dis: JAD 31(1):151–165. doi:10.3233/JAD-2012-120319
106. Saint-Pol J, Candela P, Boucau MC, Fenart L, Gosselet F (2013) Oxysterols decrease apical-to-basolateral transport of Ass peptides via an ABCB1-mediated process in an in vitro blood-brain barrier model constituted of bovine brain capillary endothelial cells. Brain Res 1517:1–15. doi:10.1016/j.brainres.2013.04.008
107. May P, Woldt E, Matz RL, Boucher P (2007) The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med 39(3):219–228. doi:10.1080/07853890701214881
108. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke; J Cereb Circ 35(11 Suppl 1):2628–2631. doi:10.1161/01.STR.0000143452.85382.d1
109. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43(3):333–344. doi:10.1016/j.neuron.2004.07.017
110. Fujiyoshi M, Tachikawa M, Ohtsuki S, Ito S, Uchida Y, Akanuma S, Kamiie J, Hashimoto T, Hosoya K, Iwatsubo T, Terasaki T (2011) Amyloid-beta peptide (1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. J Neurochem 118(3):407–415. doi:10.1111/j.1471-4159.2011.07311.x
111. Fester L, Zhou L, Butow A, Huber C, von Lossow R, Prange-Kiel J, Jarry H, Rune GM (2009) Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus 19(8):692–705. doi:10.1002/hipo.20548
112. Selvais C, D'Auria L, Tyteca D, Perrot G, Lemoine P, Troeberg L, Dedieu S, Noel A, Nagase H, Henriet P, Courtoy PJ, Marbaix E, Emonard H (2011) Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J: Off Publ Fed Am Soc Exp Biol 25(8):2770–2781. doi:10.1096/fj.10-169508
113. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72(5):1858–1862
114. Andreadis A, Brown WM, Kosik KS (1992) Structure and novel exons of the human tau gene. Biochemistry 31(43):10626–10633
115. Schoenfeld TA, Obar RA (1994) Diverse distribution and function of fibrous microtubule-associated proteins in the nervous system. Int Rev Cytol 151:67–137
116. Chin SS, Goldman JE (1996) Glial inclusions in CNS degenerative diseases. J Neuropathol Exp Neurol 55(5):499–508
117. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42(3 Pt 1):631–639
118. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging 28(3):327–335. doi:10.1016/j.neurobiolaging.2006.02.007
119. Stoothoff WH, Johnson GVW (2005) Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta (BBA) - Mol Basis Dis 1739(2–3):280–297. doi:10.1016/j.bbadis.2004.06.017
120. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10(6):1089–1099
121. Brion JP, Smith C, Couck AM, Gallo JM, Anderton BH (1993) Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer’s disease. J Neurochem 61(6):2071–2080
122. Brion JP, Octave JN, Couck AM (1994) Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. Neuroscience 63(3):895–909
123. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F (2013) Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev 12(1):289–309. doi:10.1016/j.arr.2012.06.003
124. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Terro F (2013) Tau protein phosphatases in Alzheimer’s disease: the leading role of PP2A. Ageing Res Rev 12(1):39–49. doi:10.1016/j.arr.2012.06.008
125. Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K (2012) An experimental rat model of sporadic Alzheimer’s disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol 123(1):133–151. doi:10.1007/s00401-011-0908-x
126. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118(1):53–69. doi:10.1007/s00401-009-0486-3
127. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686):702–705. doi:10.1038/31508
128. Zhang N, Yu JT, Yang Y, Yang J, Zhang W, Tan L (2011) Association analysis of GSK3B and MAPT polymorphisms with Alzheimer’s disease in Han Chinese. Brain Res 1391:147–153. doi:10.1016/j.brainres.2011.03.052
129. Kwok JB, Loy CT, Hamilton G, Lau E, Hallupp M, Williams J, Owen MJ, Broe GA, Tang N, Lam L, Powell JF, Lovestone S, Schofield PR (2008) Glycogen synthase kinase-3beta and tau genes interact in Alzheimer’s disease. Ann Neurol 64(4):446–454. doi:10.1002/ana.21476
130. Sun W, Jia J (2009) The +347 C promoter allele up-regulates MAPT expression and is associated with Alzheimer’s disease among the Chinese Han. Neurosci Lett 450(3):340–343. doi:10.1016/j.neulet.2008.11.067
131. Platt TL, Reeves VL, Murphy MP (2013) Transgenic models of Alzheimer’s disease: better utilization of existing models through viral transgenesis. Biochim Biophys Acta 1832(9):1437–1448. doi:10.1016/j.bbadis.2013.04.017
132. Auer IA, Schmidt ML, Lee VM, Curry B, Suzuki K, Shin RW, Pentchev PG, Carstea ED, Trojanowski JQ (1995) Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer’s disease. Acta Neuropathol 90(6):547–551
133. Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M (2001) Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 76(2):391–400
134. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiology of Aging 24(8):1063–1070
135. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293(5534):1491–1495. doi:10.1126/science.1062097
136. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M (2003) Amyloid beta-protein (Abeta) 1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87(3):609–619
137. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27(1):224–233. doi:10.1038/sj.emboj.7601953
138. Ghribi O, Larsen B, Schrag M, Herman MM (2006) High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 200(2):460–467. doi:10.1016/j.expneurol.2006.03.019
139. Ghribi O, Prammonjago P, Herman MM, Spaulding NK, Savory J (2003) Abeta(1-42)-induced JNK and ERK activation in rabbit hippocampus is differentially regulated by lithium but is not involved in the phosphorylation of tau. Brain Res Mol Brain Res 119(2):201–206
140. Mudher A, Lovestone S (2002) Alzheimer’s disease—do tauists and baptists finally shake hands? Trends Neurosci 25(1):22–26
141. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, Gylys KH (2008) Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes. Am J Pathol 172(6):1683–1692. doi:10.2353/ajpath.2008.070829
142. Popp J, Meichsner S, Kolsch H, Lewczuk P, Maier W, Kornhuber J, Jessen F, Lutjohann D (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer’s disease. Biochem Pharmacol 86(1):37–42. doi:10.1016/j.bcp.2012.12.007
143. Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO (2006) Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? Neurosci Lett 397(1–2):83–87. doi:10.1016/j.neulet.2005.11.046
144. Shafaati M, Solomon A, Kivipelto M, Bjorkhem I, Leoni V (2007) Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci Lett 425(2):78–82. doi:10.1016/j.neulet.2007.08.014
145. Marwarha G, Dasari B, Prasanthi JRP, Schommer J, Ghribi O (2010) Leptin reduces the accumulation of A beta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheim Dis 19(3):1007–1019. doi:10.3233/jad-2010-1298
146. Zannis VI, McPherson J, Goldberger G, Karathanasis SK, Breslow JL (1984) Synthesis, intracellular processing, and signal peptide of human apolipoprotein E. J Biol Chem 259(9):5495–5499
147. Lund-Katz S, Phillips MC (2010) High density lipoprotein structure-function and role in reverse cholesterol transport. Sub-cellular Biochem 51:183–227. doi:10.1007/978-90-481-8622-8_7
148. Leoni V, Solomon A, Kivipelto M (2010) Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment. Biochem Soc Trans 38(4):1021–1025. doi:10.1042/BST0381021
149. Glockner F, Meske V, Lutjohann D, Ohm TG (2011) Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 70(4):292–301. doi:10.1097/NEN.0b013e318212f185
150. Rahman A, Akterin S, Flores-Morales A, Crisby M, Kivipelto M, Schultzberg M, Cedazo-Minguez A (2005) High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 579(28):6411–6416. doi:10.1016/j.febslet.2005.10.024
151. Liu J, Zhu YS, Khan MA, Brunk E, Martin-Cook K, Weiner MF, Cullum CM, Lu H, Levine BD, Diaz-Arrastia R, Zhang R (2013) Global brain hypoperfusion and oxygenation in amnestic mild cognitive impairment. Alzheim Dement: J Alzheim Asso. doi:10.1016/j.jalz.2013.04.507
152. Hauser T, Schonknecht P, Thomann PA, Gerigk L, Schroder J, Henze R, Radbruch A, Essig M (2013) Regional cerebral perfusion alterations in patients with mild cognitive impairment and Alzheimer disease using dynamic susceptibility contrast MRI. Acad Radiol 20(6):705–711. doi:10.1016/j.acra.2013.01.020
153. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234(3):851–859. doi:10.1148/radiol.2343040197
154. Bradley KM, O'Sullivan VT, Soper ND, Nagy Z, King EM, Smith AD, Shepstone BJ (2002) Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer’s disease. Brain: J Neurol 125(Pt 8):1772–1781
155. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28(4):202–208. doi:10.1016/j.tins.2005.02.001
156. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA:J Am Med Assoc 277(10):813–817
157. Rj OB (2011) Vascular dementia: atherosclerosis, cognition and Alzheimer’s disease. Curr Alzheimer Res 8(4):341–344
158. Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109(5–6):813–836. doi:10.1007/s007020200068
159. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE (1998) Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer’s disease. Am J Pathol 153(3):725–733
160. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7(9):954–960. doi:10.1038/nn1302
161. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70(6):871–880. doi:10.1002/ana.22516
162. Cordonnier C, van der Flier WM (2011) Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain:J Neurol 134(Pt 2):335–344. doi:10.1093/brain/awq321
163. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P, van der Flier WM (2009) Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke; J Cereb Circ 40(4):1269–1274. doi:10.1161/STROKEAHA.108.531343
164. Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L (2010) Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 285(47):36958–36968. doi:10.1074/jbc.M110.127829
165. Lefterov I, Fitz NF, Cronican AA, Fogg A, Lefterov P, Kodali R, Wetzel R, Koldamova R (2010) Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J Biol Chem 285(47):36945–36957. doi:10.1074/jbc.M110.127738
166. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol 120(2):169–183. doi:10.1007/s00401-010-0707-9
167. Ruzali WA, Kehoe PG, Love S (2013) Influence of LRP-1 and apolipoprotein E on amyloid-beta uptake and toxicity to cerebrovascular smooth muscle cells. J Alzheim Dis: JAD 33(1):95–110. doi:10.3233/JAD-2012-121336
168. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV (2009) SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 11(2):143–153. doi:10.1038/ncb1819
169. Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S (2010) Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc Natl Acad Sci U S A 107(48):20816–20821. doi:10.1073/pnas.1005888107
170. Olaisen B, Teisberg P, Gedde-Dahl T Jr (1982) The locus for apolipoprotein E (apoE) is linked to the complement component C3 (C3) locus on chromosome 19 in man. Hum Genet 62(3):233–236
171. Sadigh-Eteghad S, Talebi M, Farhoudi M (2012) Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer’s disease. A meta-analysis. Neurosciences 17(4):321–326
172. Tan L, Yu JT, Zhang W, Wu ZC, Zhang Q, Liu QY, Wang W, Wang HF, Ma XY, Cui WZ (2013) Association of GWAS-linked loci with late-onset Alzheimer’s disease in a northern Han Chinese population. Alzheim Dement: J Alzheim Assoc 9(5):546–553. doi:10.1016/j.jalz.2012.08.007
173. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106–118. doi:10.1038/nrneurol.2012.263
174. Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lutjohann D, Broersen LM, Hartmann T, Michaelson DM (2012) The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheim Dis: JAD 28(3):667–683. doi:10.3233/JAD-2011-111265
175. Stein EA (2003) The power of statins: aggressive lipid lowering. Clin Cardiol 26(4 Suppl 3):III25–III31
176. Cibickova L (2011) Statins and their influence on brain cholesterol. J Clin Lipidol 5(5):373–379. doi:10.1016/j.jacl.2011.06.007
177. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98(10):5856–5861. doi:10.1073/pnas.081620098
178. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2(1):e18. doi:10.1371/journal.pmed.0020018
179. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282(37):26832–26844. doi:10.1074/jbc.M702640200
180. Sagare AP, Deane R, Zlokovic BV (2012) Low-density lipoprotein receptor-related protein 1: a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther 136(1):94–105. doi:10.1016/j.pharmthera.2012.07.008
181. Metais C, Brennan K, Mably AJ, Scott M, Walsh DM, Herron CE (2013) Simvastatin treatment preserves synaptic plasticity in AbetaPPswe/PS1dE9 mice. J Alzheim Dis: JAD. doi:10.3233/JAD-130257
182. Matsuzawa A, Ichijo H (2008) Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 1780(11):1325–1336. doi:10.1016/j.bbagen.2007.12.011
183. Zhao Z, Zhao S, Xu N, Yu C, Guan S, Liu X, Huang L, Liao W, Jia W (2010) Lovastatin improves neurological outcome after nucleus basalis magnocellularis lesion in rats. Neuroscience 167(3):954–963. doi:10.1016/j.neuroscience.2010.02.054
184. Tong XK, Lecrux C, Rosa-Neto P, Hamel E (2012) Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits. J Neurosci: Off J Soc Neuroscience 32(14):4705–4715. doi:10.1523/JNEUROSCI.0169-12.2012
185. Kou J, Song M, Pattanayak A, Lim JE, Yang J, Cao D, Li L, Fukuchi K (2012) Combined treatment of Abeta immunization with statin in a mouse model of Alzheimer’s disease. J Neuroimmunol 244(1–2):70–83. doi:10.1016/j.jneuroim.2012.01.008
186. Hamano T, Yen SH, Gendron T, Ko LW, Kuriyama M (2012) Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging 33(10):2306–2320. doi:10.1016/j.neurobiolaging.2011.10.020
187. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10):1439–1443
188. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59(3):378–384
189. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M (2002) Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc 50(11):1852–1856
190. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62(7):1047–1051. doi:10.1001/archneur.62.7.1047
191. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC, Cache County Study i (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62(2):217–224. doi:10.1001/archpsyc.62.2.217
192. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF (2012) The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 10(5):296–302. doi:10.1016/j.amjopharm.2012.08.002
193. Hoglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K (2005) Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer’s disease. Exp Brain Res Exp Hirnforschung Exp Cereb 164(2):205–214. doi:10.1007/s00221-005-2243-8
194. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61(3):333–337. doi:10.1001/archneur.61.3.333
195. Serrano-Pozo A, Vega GL, Lutjohann D, Locascio JJ, Tennis MK, Deng A, Atri A, Hyman BT, Irizarry MC, Growdon JH (2010) Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheim Dis Assoc Disord 24(3):220–226. doi:10.1097/WAD.0b013e3181d61fea
196. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S (2008) Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J Alzheim Dis: JAD 13(2):187–197
197. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P (2005) Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2(5):527–539
198. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5:20. doi:10.1186/1741-7015-5-20
199. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P (2006) Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 185:3–7. doi:10.1111/j.1600-0404.2006.00690.x
200. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62(5):753–757. doi:10.1001/archneur.62.5.753
201. Carlsson CM, Xu G, Wen Z, Barnet JH, Blazel HM, Chappell RJ, Stein JH, Asthana S, Sager MA, Alsop DC, Rowley HA, Fain SB, Johnson SC (2012) Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study. Curr Alzheimer Res 9(8):990–997
202. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER (2006) Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheim Dis: JAD 10(4):399–406
203. Chang TY, Chang CC, Cheng D (1997) Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem 66:613–638. doi:10.1146/annurev.biochem.66.1.613
204. Bhattacharyya R, Kovacs DM (2010) ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801(8):960–965. doi:10.1016/j.bbalip.2010.04.003
205. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3(10):905–912. doi:10.1038/ncb1001-905
206. Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, Frosch MP, Hutter-Paier B, Windisch M, Kovacs DM (2010) The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J Neuropathol Exp Neurol 69(8):777–788. doi:10.1097/NEN.0b013e3181e77ed9
207. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44(2):227–238. doi:10.1016/j.neuron.2004.08.043
208. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY (2010) ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A 107(7):3081–3086. doi:10.1073/pnas.0913828107
209. Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM (2009) Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J: Off Publ Fed Am Soc Exp Biol 23(11):3819–3828. doi:10.1096/fj.09-134999
210. Bhattacharyya R, Barren C, Kovacs DM (2013) Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J Neurosci: Off J Soc Neurosci 33(27):11169–11183. doi:10.1523/JNEUROSCI.4704-12.2013
211. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M (1994) A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14(10):7025–7035
212. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA (2002) Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 16(6):1378–1385. doi:10.1210/mend.16.6.0835
213. Fan J, Donkin J, Wellington C (2009) Greasing the wheels of Abeta clearance in Alzheimer’s disease: the role of lipids and apolipoprotein E. BioFactors 35(3):239–248. doi:10.1002/biof.37
214. Namjoshi DR, Martin G, Donkin J, Wilkinson A, Stukas S, Fan J, Carr M, Tabarestani S, Wuerth K, Hancock RE, Wellington CL (2013) The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E. PLoS One 8(1):e53529. doi:10.1371/journal.pone.0053529
215. Wang Q, Wang S, Shi Y, Yao M, Hou L, Jiang L (2014) Reduction of liver X receptor beta expression in primary rat neurons by antisense oligodeoxynucleotides decreases secreted amyloid beta levels. Neurosci Lett. doi:10.1016/j.neulet.2013.12.055
216. Cui W, Sun Y, Wang Z, Xu C, Xu L, Wang F, Chen Z, Peng Y, Li R (2011) Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels. Neurochem Res 36(10):1910–1921. doi:10.1007/s11064-011-0513-3
217. Wang L, Zhang X, Lu Y, Tian M, Li Y (2014) Dynamic changes of Apo A1 mediated by LXR/RXR/ABCA1 pathway in brains of the aging rats with cerebral hypoperfusion. Brain Res Bull 100:84–92. doi:10.1016/j.brainresbull.2013.11.004
218. Stukas S, May S, Wilkinson A, Chan J, Donkin J, Wellington CL (2012) The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1. Biochim Biophys Acta 1821(3):536–546. doi:10.1016/j.bbalip.2011.08.014
219. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS (2007) The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer’s disease. Mol Cell Neurosci 34(4):621–628. doi:10.1016/j.mcn.2007.01.011
220. Aicardi G (2013) New hope from an old drug: fighting Alzheimer’s disease with the cancer drug bexarotene (targretin)? Rejuvenation Res 16(6):524–528. doi:10.1089/rej.2013.1497
221. Lefebvre P, Benomar Y, Staels B (2010) Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab: TEM 21(11):676–683. doi:10.1016/j.tem.2010.06.009
222. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503–1506. doi:10.1126/science.1217697